These 3 ASX biotech shares are all up at least 120% in a year These 3 biotech shares have gone gangbusters across the past 12 months. Multi Asset Portfolio Strategist at Zecca Capital Partners Zach is a hedge fund analyst with an extensive background in equities and portfolio management. Alongside to contributing The Motley Fool, he works in portfolio strategy with a multi-asset and multi-strategy hedge fund manager. As such, he has a unique approach to research and investing, taking a top town approach to identify unique value propositions that sit within his circle of competence. Zach enjoys the more foolish things in life, in addition to Rugby.